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A B S T R A C T
Acute promyelocytic leukemia (APL) is a form of acute leukemia with a characteristic translocation,
t(15;17), and is considered a hematologic emergency, typically treated with all-trans retinoic acid and an
anthracycline. We present the case of a young, gravid woman who was diagnosed with APL in the third
trimester, initiated typical treatment, and suffered uncommon cardiac complications.
<Learning objective: Myopericarditis is not a side effect often encountered in the management of acute
promyelocytic leukemia with alpha t-retinoic acid, and its mechanism is incompletely understood but
possibly related to the differentiation syndrome. This complication can be effectively treated with
systemic glucocorticoids, supportive care, and withdrawal of the offending agent, even in the pregnant
population.>
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Acute promyelocytic leukemia (APL) is an M3 form of acute
leukemia with a characteristic translocation t(15;17) and is
considered a hematologic emergency. Leukemia generally affects
1 in 70,000 pregnancies, a subset at higher risk of morbidity and
mortality by virtue of underlying physiologic stress and potential
placental transfer of chemotherapeutics. APL presents more
commonly relative to other myeloid leukemias in pregnancy
due to its higher prevalence in younger populations [1,2]. Among
treated, non-pregnant APL patients in the general population,
survival rates exceed 70% [3]. Similar outcome data in pregnant
patients with treated APL are not available, but case reports of
successful therapy have been published. Management of APL in
pregnancy varies by trimester at diagnosis [1,4]. The most
commonly used regimens involve high-dose all-trans retinoic
acid (ATRA) along with an anthracycline both of which can have
signiﬁcant cardiotoxic effects. The case that follows is of a young,
gravid woman who was diagnosed with APL in the third trimester
with ensuing complications.* Corresponding author at: OHSU Division of General Internal Medicine, 3181 SW
Sam Jackson Park Road L475, Portland, OR 97239-3098, USA. Tel.: +1 503 494 6551;
fax: +1 503 494 0979.
E-mail addresses: oehler@ohsu.edu, oehlerd@gmail.com (A. Oehler).
http://dx.doi.org/10.1016/j.jccase.2014.07.010
1878-5409/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightCase report
A 24-year-old obese woman with history of a prior pregnancy
complicated by preeclampsia was admitted to an outside hospital
for easy bruising and headaches at 27 and 1/7 weeks pregnancy. On
presentation, she was found to be pancytopenic, with an initial
white blood cell (WBC) count of 1.0  109/L. Bone marrow biopsy
revealed an abnormally elevated number of myeloid blasts.
Cytogenetic studies indicated t(15;17) consistent with APL. ATRA
was initiated on day 4 of admission at a dose of 45 mg/m2/day,
with dexamethasone to induce fetal lung maturity. Cell counts
were supported with intermittent packed red blood cell and
platelet transfusions. At day 7 she was transferred to a tertiary
center for further management of this complicated pregnancy.
ATRA therapy was continued after transfer. Idarubicin at a dose
of 12 mg/m2 and prednisone were also initiated (for four total
doses on days 21, 23, 25, and 27). On the evening of day 26, the
22nd day of ATRA therapy, she developed substernal, sharp chest
pain radiating to the back, worse with deep inspiration, and
positional changes. She had been tachycardic throughout with a
heart rate ranging from 120 to 140 bpm, but she was afebrile.
Systolic BP had ranged from 110 to 140 mmHg over the previous
24 h. Physical examination revealed tachycardia with a regular
rhythm. S1 and S2 were normal. A ventricular gallop was present.
There was a Grade I pericardial rub, with the patient leaning
forward at end expiration. Hemogram was remarkable for WBC
count of 9.8  109/L with a neutrophilic predominance. Serums reserved.
Table 1 Timeline of laboratory abnormalities.
Day 0 8 26 33
Event Day of admission Day of transfer Onset of symptoms Resolution of symptoms
WBC (109/L) 1.2 2.2 9.7 0.26
Hct (%) 24.2 23.2 25.3 29.8
Plt (103/mm3) 8 26 41 11
Sodium (mmol/L) 136 139 135 133
Potassium (mmol/L) 3.8 3.8 4.1 3.7
Chloride (mmol/L) 105 109 105 101
Bicarbonate (mmol/L) 23 22 22 24
BUN (mg/dL) 6 8 8 7
Cr (mg/dL) 0.5 0.5 0.4 0.51
Troponin (ng/mL) 3.66 1.26a
NT-proBNP (pg/mL) 2877
WBC, white blood cells; Hct, hematocrit; Plt, platelets; BUN, blood urea nitrogen; Cr, creatinine; BNP, B-type natriuretic peptide.
a Specimen collected on day 27 and was the last known troponin prior to resolution of symptoms.
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0.56 mg/dL. B-type natriuretic peptide was elevated at 2877 pg/
mL. Troponin was elevated at 3.66 ng/mL. See Table 1 for timeline
of laboratory abnormalities. An electrocardiogram (ECG) revealed
ST elevations with associated PR depressions (Fig. 1). A chest X-ray
was signiﬁcant for hydrostatic pulmonary edema and normal heart
size. Computed tomography angiography of the chest did not
reveal evidence of pulmonary embolism or consolidation. A trans-
thoracic echocardiogram showed a small, circumferential pericar-
dial effusion (Fig. 2) with multiple segmental wall motion
abnormalities in a non-coronary distribution. The estimated
ejection fraction was mildly reduced, at 45%. The constellation
of ﬁndings was felt to be consistent with acute myopericarditis in
the setting of ATRA and idarubicin therapy.
ATRA and idarubicin were immediately discontinued due to
concern for acute cardiotoxic effects. Prednisone 60 mg daily was
initiated to treat the myopericarditis. Chest pain improved only
after an increase in prednisone dosage to 80 mg daily. Metoprolol
was added for arrhythmia prophylaxis and treatment of cardio-
myopathy. Hydralazine and isosorbide dinitrate were used forFig. 1.
12-lead electrocardiogram from day 26 with chest pain. Notice ST segment el
indicative of both ventricular and atrial epicardial inﬂammation.afterload reduction. Low-dose furosemide was given for diuresis as
needed. The patient developed a brief, symptomatic episode of
atrial ﬁbrillation with rapid ventricular response on hospital day
31 with spontaneous conversion to sinus rhythm. The metoprolol
dose was subsequently increased. No further atrial or ventricular
arrhythmias occurred.
Chest pain resolved completely 7 days after initiation of
prednisone. Troponin down trended. A repeat transthoracic
echocardiogram at admission day 40 showed normalization of
left ventricular function and segmental wall motion abnormalities.
The pericardial effusion was no longer present. There was no
evidence of pericardial constriction.
The patient’s course was further complicated by Gram-negative
bacteremia and hyperglycemia secondary to steroid administra-
tion. Labor was induced, and she delivered vaginally at 34 weeks
with an estimated blood loss of 200 mL. The baby was healthy with
only a brief hospital stay for hyperbilirubinemia. The patient was
discharged shortly after delivery with plans for outpatient
consolidation chemotherapy. A slow prednisone taper of 10 mg
per week was recommended. Metoprolol was continued. Therapyevations in leads I, II, aVL, and V3–V6 with PR depressions in the associated leads
Fig. 2. Parasternal long-axis view demonstrating a posterior pericardial effusion (see arrow).
A. Oehler, S. Shah / Journal of Cardiology Cases 10 (2014) 200–203202with an angiotensin-converting enzyme inhibitor was initiated,
and isosorbide dinitrate and hydralazine were discontinued.
Discussion
This patient developed myopericarditis in the setting of third
trimester pregnancy, APL, and administration of ATRA and
idarubicin. The acute cardiotoxic effects were resolved with the
discontinuation of ATRA and idarubicin, initiation of high-dose
prednisone, and standard heart failure therapy. The differential
diagnosis for her syndrome included: takotsubo cardiomyopathy,
anthracycline-induced cardiomyopathy, ATRA-induced myoper-
icarditis, viral myocarditis, and peripartum cardiomyopathy.
Acute myopericarditis is a known, rare complication of ATRA
therapy in the setting of APL with a total of 6 reported cases [5–9],
but it has never been reported in pregnancy. One case reported
histological ﬁndings on autopsy of APL cells inﬁltrating the
myocardium in this setting, suggesting pathophysiologic correla-
tion with differentiation syndrome [7]. Differentiation syndrome
(DS) is a complication of APL therapy with ATRA due to rapid
therapeutic differentiation of undifferentiated peripheral promye-
locytes leading to tissue inﬁltration of cells. Myopericarditis
traditionally lies outside the recognized pattern of DS, typically
presenting clinically as unexplained fever, weight gain, peripheral
edema, dyspnea with interstitial inﬁltrates, pleuropericardial
effusion, hypotension, and acute kidney injury [10]. Differentiation
syndrome occurs in 2–31% of patients receiving induction therapy
depending on adjunctive agents administered with ATRA (anthra-
cyclines diminish this risk) and the presence of other risk factors,
including elevated WBC count at start of therapy, peak WBC count
during therapy, elevated body mass index (BMI), and creatinine
level [10–12]. Our patient did have a signiﬁcantly elevated BMI,
although WBC count at onset of therapy was unremarkable. The
syndrome carries a mortality rate in non-pregnant populations
from 2% to 10% [13]. Management typically includes stoppage of
ATRA and initiation of steroid immunosuppression.The patient also recently received idarubicin, so the question
arises about the contribution of anthracycline toxicity. There are
three known time frames of toxicity: early, chronic, and late onset.
Early onset toxicity can occur anytime in the acute phase following
initiation of idarubicin therapy, is dose-dependent, and characteris-
tically involves high rates of atrial and ventricular arrhythmias
[14,15]. Our patient received a relatively low total dose of idarubicin,
48 mg/m2, well under the prescribed toxic point of 350 mg/m2 [16].
In addition, she had only one self-limited episode of an atrial
arrhythmia. In the setting of receiving ATRA therapy, acute
anthracycline-induced cardiotoxicity was felt to be less likely.
Takotsubo and peripartum cardiomyopathy (CM) were also
entertained in the differential; however her echocardiographic
wall motion pattern was not consistent with takotsubo (i.e. basal
segment hypokinesis with apical ballooning). Peripartum CM can
present in the last trimester of pregnancy, but typically does not
involve the pericardium [17]. A viral myopericarditis was felt to be
unlikely given a more proximal culprit, the ATRA therapy, and the
patient’s lack of a viral prodrome [18].
Classic ﬁndings of myopericarditis on transthoracic echocar-
diogram often include a pericardial effusion, with segmental left
ventricular wall motion abnormalities and depressed left ventric-
ular ejection fraction. Cardiac biomarkers are also typically
elevated. Prognosis varies by etiology, but reported mortality
rates for biopsy-veriﬁed myocarditis are upwards of 20% and 56%
at 1 and 4 years [19]. Treatment of myopericarditis is largely
supportive, namely with the initiation of standard heart failure
therapy [20]. Few rigorous comparisons have been drawn between
therapies for various etiologies of the syndrome. Therapy for
isolated pericarditis focuses speciﬁcally on symptom control with
anti-inﬂammatory medications including aspirin, non-steroidal
anti-inﬂammatory drugs (NSAIDs), colchicine, and prednisone.
Non-aspirin NSAIDs have not traditionally been used in treatment
of pericarditis when myocardium is involved due to the risk of poor
scar formation and wound healing [21]. Therapeutic modalities
available in the pregnant patient with myocarditis, pericarditis, or
myopericarditis are limited (Table 2) by fetal concerns [22].
Table 2 Treatment modalities for acute pericarditis in the gravid female.
Medication FDA Pregnancy Risk
Classiﬁcationa
All NSAIDs Class D
Aspirin <100 mg/day Class B
Prednisone Class B
Colchicine Class C
FDA, Food and Drug Administration; NSAIDs, non-steroidal anti-inﬂam-
matory drugs.
a Class A: Adequate studies fail to demonstrate risk to fetus in ﬁrst
trimester. Class B: No adequate studies, but animal studies do not
demonstrate risk. Class C: No adequate studies, but animal studies have
shown an adverse effect in the fetus. Class D: Positive evidence of human
fetal risk based on adverse reaction data, but beneﬁt may outweigh risk.
Class X: Positive evidence of human fetal risk based on adverse reaction
data, and risk clearly outweighs beneﬁt.
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never been reported. In this setting, it can be difﬁcult to identify the
true inciting agent amongst a plethora of potential toxic agents.
ATRA is the most likely culprit for reasons described above, although
the mechanism of insult, whether by direct toxicity or leukemic
inﬁltration, remains unclear. A management strategy similar to the
non-pregnant patient was used. Future studies will be limited by the
low prevalence of this treatment complication, but may focus on
duration of therapy, as the side effects of prednisone in the pregnant
population are accentuated by fetal concerns.
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